Invest KOREA

There are concerns about a shortage of insulin that will increase demand by
more than 20% in 2030 due to a surge in diabetes patients worldwide.
In Korea, all insulin is imported, and in advanced countries,
the price of insulin has become a social problem due to price-fixing
and market monopoly by global pharmaceutical companies.
So, the technology to produce low-priced, high-quality insulin is important.
Undbio has developed high-purity/high-yield insulin that
dramatically increased production yield using the following technologies
and is aiming for commercial manufacturing.

- Bio-better Technology
(extra-long-lasting insulin injection of bio-better technology,
injection one a week, reducing the number of injections)
- Recombinant Technology
(building host cell lines that produce high-purity insulin and insulin analog products
with the latest gene recombination technology)
- Platform Technology
(manufacturing all insulin and insulin analog products at the same facility)
- Vertical Integration Technology
(vertically integrated manufacturing technology for pharmaceuticals and finished products)

In November 2021, we filed an international patent application for PCT
for ultra-long-acting insulin injection (bio-better)
and completed the Proof of Concept (PoC) for insulin glargine, lispro, and human insulin.
In the future, after undergoing global clinical trials,
we aim to register the products in Korea and the United States in 2026.
We plan to enter the global market in 2027 by building a cGMP facility
producing insulin raw materials and finished products.